We are live on ! Find out more
LVTX

LAVA Therapeutics
LVTX

Delisted

LVTX was delisted on the 20th of November, 2025.

Back to rankings

18 hedge funds and large institutions have $35.2M invested in LAVA Therapeutics in 2022 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.23% less ownership

Funds ownership: 31.24% → 31.01% (-0.23%)

10% less funds holding

Funds holding: 20 → 18 (-2)

21% less capital invested

Capital invested by funds: $44.3M → $35.2M (-$9.12M)

40% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 5

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
18
Holders Change
-2
Holders Change %
-10%
% of All Funds
0.28%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
3
Reduced
5
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$556K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$5.27K
3
Axa
Axa
France
+$10

Top Sellers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
-$758K
2
NCM
Nantahala Capital Management
Connecticut
-$135K
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$11K
4
Morgan Stanley
Morgan Stanley
New York
-$7.75K
5
UBS Group
UBS Group
Switzerland
-$2.66K
Name Holding Trade Value Shares
Change 		Change in
Stake
NHAS
1
Novo Holdings A/S
Denmark
$14.6M – – –
RG
2
Redmile Group
California
$12.4M – – –
NIP
3
Nicholas Investment Partners
California
$2.31M – – –
NCM
4
Nantahala Capital Management
Connecticut
$1.47M -$135K -26,644 -7%
Axa
5
Axa
France
$1.02M +$10 +2 +0%
AG
6
Artal Group
Luxembourg
$880K – – –
Millennium Management
7
Millennium Management
New York
$663K +$556K +109,392 +265%
DCM
8
DAFNA Capital Management
California
$613K – – –
AWG
9
Alpha Wave Global
New York
$533K – – –
Point72 Asset Management
10
Point72 Asset Management
Connecticut
$515K -$11K -2,171 -2%
Bank of New York Mellon
11
Bank of New York Mellon
New York
$78K – – –
Geode Capital Management
12
Geode Capital Management
Massachusetts
$48K +$5.27K +1,038 +10%
Morgan Stanley
13
Morgan Stanley
New York
$12K -$7.75K -1,525 -35%
UBS Group
14
UBS Group
Switzerland
$5K -$2.66K -523 -30%
PHK
15
Point72 Hong Kong
Hong Kong
$3K – – –
TFGT
16
TS Financial Group (TSFG)
Illinois
$2K – – –
SFM
17
Sphera Funds Management
Israel
– -$758K -137,857 Closed
CSS
18
Cubist Systematic Strategies
Connecticut
– -$1.52K -300 -75%

LVTX Hedge Fund Activity: Q1 2022 in Review

18 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in LAVA Therapeutics (LVTX) for Q1 2022, worth a combined $35.2M — down 21% from $44.3M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of LVTX and 0 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 3 added.

The largest buyer was Millennium Management, adding an estimated $556K. The largest seller was Sphera Funds Management, exiting entirely with an estimated $758K sold.

  • 18 institutional investors held LAVA Therapeutics (LVTX) as of Q1 2022, down from 20 in Q4 2021.
  • Funds reported $35.2M of LAVA Therapeutics stock for Q1 2022, down 21% quarter-over-quarter.
  • 0 funds opened new LAVA Therapeutics positions in Q1 2022 and 2 closed out, a net change of -2 holders.
  • The largest LAVA Therapeutics buyer in Q1 2022 was Millennium Management, an estimated $556K added.
  • The largest LAVA Therapeutics seller in Q1 2022 was Sphera Funds Management, an estimated $758K sold.

Based on aggregated 13F filings for Q1 2022.